Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , July 13, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between March 1, 2021 and February 25, 2022.

VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

BENSALEM, Pa. , July 12, 2023 /PRNewswire/ -- Law Offices of Howard G.

VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

NEW YORK , July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc.. Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Viatris Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 14, 2023 - (NASDAQ: VTRS)

NEW YORK , July 11, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ: VTRS), and certain officers. The class action, filed in the United States District Court for the Western District of Pennsylvania and docketed under 23-cv-01098, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Viatris common stock between March 1, 2021 and February 25, 2022, inclusive (the "Class Period"), seeking remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Viatris, Inc. of Class Action Lawsuit and Upcoming Deadline - VTRS

NEW YORK , July 10, 2023 /PRNewswire/ -- Attention Viatris Inc. ("Viatris") (NASDAQ: VTRS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 1, 2021 and February 25, 2022. If you suffered a loss on your investment in Viatris, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Viatris Investors of a Lead Plaintiff Deadline of July 14, 2023

CVS Health

Truist Financial

Viatris is a generic drugmaker formed from a merger between Pfizer's generic drug division and Mylan. CVS Health is famous for its pharmacy chain, but it's the parts of its business you might not know about that make it a great dividend stock.

3 Beaten-Down Dividend Stocks That Look Like Bargains Right Now

NEW YORK , July 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS

Loews

WestRock

The move to share repurchases over the last few years has made the price-to-book ratio less reliable for finding hidden opportunities in stocks. How's that, you ask?

3 Stocks to Snag for Less Than Book Value

AbbVie

CareTrust REIT

If you worry you won't have enough saved up by retirement, dividend stocks can help boost your income. Allocating part of your retirement savings to such equities can reduce depletion of your savings.

Why Dividend Stocks Should Be a Key Part of Your Retirement Plan

Viatris is growing while slashing costs and returning capital to investors. It has plans to onboard even more new sources of revenue, but it'll take a while.

Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?

NEW YORK , June 30, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS

PITTSBURGH , June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer  Scott A.

Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023

V.F.

Warner Bros Discovery Inc

In recent years, S&P 500 companies with new chief executive officers (CEOs) have become a regular occurrence. That's because CEOs are moving on more quickly — both by choice and because of activist investors — and that means there are always interesting possibilities for stocks set to rally under new CEOs.

Fresh Blood: 3 Stocks Ready to Rally Under New CEOs

Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.

Viatris (VTRS) Flat As Market Gains: What You Should Know

Fintel reports that on June 23, 2023, Barclays downgraded their outlook for Viatris (NASDAQ:VTRS) from Equal-Weight to Underweight.

Barclays Downgrades Viatris

NEW YORK , June 20, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

Viatris, a healthcare company, faces weakening fundamentals and significant risks, including uncertainty regarding its execution plan. Despite these challenges, the company has growth opportunities, with over $3 billion in annual sales expected to mature in the next three years. VTRS stock is currently a Hold, as the company needs to demonstrate better execution and stabilize its declining top and bottom lines before it becomes a buy again.

Despite Its Valuation, Viatris Is Still A Hold

Ares Capital

Crown Castle International

Golub Capital BDC

Vitesse Energy Inc

Warren Buffett owns five stocks with dividend yields of 4.9% or higher. Four of the five belong to the portfolio of one of Berkshire Hathaway's subsidiaries.

Warren Buffett Owns These 5 High-Yield Dividend Stocks. Should You?

NEW YORK , June 16, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ: VTRS), and certain officers.  The class action, filed in the United States District Court for the Western District of Pennsylvania and docketed under 23-cv-01098, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Viatris common stock between March 1, 2021 and February 25, 2022, inclusive (the "Class Period"), seeking remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

Pomerantz Law Firm Announces the Filing of a Class Action Against Viatris, Inc. and Certain Officers - VTRS

Viatris remains a dirt cheap stock in a frothy market and pays a well-covered dividend yield. It continues to make progress towards deleveraging, and could return substantial capital to shareholders in 2024. With market sentiment working against the stock, it could deliver potentially strong total returns for investors should the tide change.

Viatris: Won't Take Much To Move The Needle

NEW YORK , June 13, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 44th Annual Global Healthcare Conference June 13, 2023 4:20 PM ET Company Participants Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Well, good afternoon, everyone.

Viatris Inc. (VTRS) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

NEW YORK--(BUSINESS WIRE)---- $VTRS #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Pennsylvania on behalf of those who acquired Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities during the period from March 1, 2021 through February 25, 2022 (the “Class Period”). Investors have until July 14, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Viatris is a global he.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Viatris, Inc. (VTRS) Investors and Encourages Investors to Contact the Firm Before July 14, 2023

NEW YORK , June 10, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) and reminds investors of the July 14, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Viatris stock or options between March 1, 2021 and February 25, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

VIATRIS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options

Enbridge

Viatris generates ample cash flow to pay down its debt and support its above-average dividend yield. Enbridge's payout ratio based on net income may look alarming, but the company's dividend is safer than it looks.

News for Viatris Stock (VTRS)